Comparing Self Monitored Blood Glucose (SMBG) to Continuous Glucose Monitoring (CGM) in Type 2 Diabetes

Completed · Not applicable

Conditions studied: Type 2 Diabetes

In brief

The purpose of this study is to evaluate the use of SMBG and CGM for clinical decisions related to the management of type 2 diabetes. The secondary objective is to determine the benefit of using CGM for clinical diabetes management decision-making.

Key facts

Study ID

NCT01237301

Run by

HealthPartners Institute

People needed

124

Starts

2010-10-01

Expected to finish

2012-03-01

Last updated by the study team

2018-10-17

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female ≥18 and ≤75 years of age (Upper range to assure dexterity for use of CGM)
• Clinical diagnosis of type 2 diabetes
• HbA1c ≥7.0%
• Diabetes can be treated with any of the following therapies within one month prior to study enrollment: (1) medical nutrition therapy alone or with metformin; (2) sulfonylurea with or without metformin; (3) dipeptidyl peptidase 4 (DPP-4) inhibitor or Glucagon-like peptide-1 (GLP-1) agonist with or without metformin; or insulin with or without metformin.

You may not qualify if…

• Treated with Thiazolidinediones (TZD)
• Administered prednisone or cortisone medications in the previous 30 days
• Currently pregnant or planning pregnancy during the study period
• Presence of any severe medical or psychological condition or chronic conditions/infections that in the opinion of the Investigator would compromise the subject's safety or successful participation in the study
• HbA1c <7.0%
• Unable to follow the study protocol
• Unable to speak, read and write in English

Where it is running

• International Diabetes Center — Minneapolis, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.